Evaluation of physicochemical properties and in vivo efficiency of atorvastatin calcium/ezetimibe solid dispersions.

Fixed-dose combination of atorvastatin calcium (ATV) and ezetimibe (EZT) provides a considerable advantage in the management of hyperlipidemia. However, both ATV and EZT suffer from the poor aqueous solubility, which can limit their oral bioavailability. The aim of the present study was to improve the in vitro performance and evaluate the in vivo efficiency of the improved (ATV/EZT) fixed-dose combination. The formulation was prepared through solid dispersion (SD)technique, using Polyvinylpyrrolidone K30 via solvent method. Solid-state analysis and the in vitro drug release of the prepared formulations were also assessed. In order to estimate the therapeutic efficiency of the prepared SDs, in vivo studies including measurement of serum lipid levels, liver index and histological analysis of the liver tissue in hyperlipidemic rats were conducted. Differential scanning calorimetry (DSC) and powder X-ray diffractometry (PXRD) showed that the drugs crystallinity was notably decreased during the preparation process. All SDs showed enhanced release for both drugs compared to their binary mixture, drugs: polymer physical mixtures (PMs) and marketed product. Administration of ATV/EZT SD led to a remarkable decrease (P<0.05) in the serum levels of total cholesterol (TC) and LDL-C in the high fat diet-induced hyperlipidemic rats compared to the PM. Additionally, the histopathological examination of the liver tissue revealed the improved efficiency of the SDs on the liver steatosis. According to the obtained results, ATV/EZT SD with improved physicochemical characteristics, showed favorable effects on the serum lipid levels and liver steatosis.

[1]  M. Rashidi,et al.  Simultaneous spectrofluorimetric and spectrophotometric determination of melatonin and pyridoxine in pharmaceutical preparations by multivariate calibration methods. , 2005, Farmaco.

[2]  M. Kang,et al.  Improved oral absorption and chemical stability of everolimus via preparation of solid dispersion using solvent wetting technique. , 2014, International journal of pharmaceutics.

[3]  K. Adibkia,et al.  Comparison of physicochemical characteristics and drug release of diclofenac sodium–eudragit® RS100 nanoparticles and solid dispersions , 2012 .

[4]  Mohammed Jemal,et al.  Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. , 2004, International journal of pharmaceutics.

[5]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  Xihong Zhao,et al.  Comparison of Dietary Control and Atorvastatin on High Fat Diet Induced Hepatic Steatosis and Hyperlipidemia in Rats , 2011, Lipids in Health and Disease.

[7]  H. Bays,et al.  Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. , 2013, The American journal of cardiology.

[8]  Bhupinder Singh,et al.  Development of optimized supersaturable self-nanoemulsifying systems of ezetimibe: effect of polymers and efflux transporters , 2014, Expert opinion on drug delivery.

[9]  S. Davaran,et al.  Triamcinolone acetonide–Eudragit® RS100 nanofibers and nanobeads: Morphological and physicochemical characterization , 2016, Artificial cells, nanomedicine, and biotechnology.

[10]  Ayman Yahia Waddad,et al.  Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex. , 2012, Die Pharmazie.

[11]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[12]  A. Navalón,et al.  Simultaneous spectrofluorimetric determination of (acetyl)salicylic acid, codeine and pyridoxine in pharmaceutical preparations using partial least-squares multivariate calibration. , 2000, Journal of pharmaceutical and biomedical analysis.

[13]  Quansheng Chen,et al.  Determination of total polyphenols content in green tea using FT-NIR spectroscopy and different PLS algorithms. , 2008, Journal of pharmaceutical and biomedical analysis.

[14]  P. Arnaud,et al.  In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. , 2001, International journal of pharmaceutics.

[15]  N. Maeda,et al.  Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis , 2008, Hepatology.

[16]  R. Neubert,et al.  Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  L. Jia,et al.  Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. , 2011, Annual review of physiology.

[18]  Y. Horsmans,et al.  Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors , 1996, Clinical pharmacokinetics.

[19]  E. Squillante,et al.  Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. , 2004, International journal of pharmaceutics.

[20]  G. R. Warnick,et al.  Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. , 1990, Clinical chemistry.

[21]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  D. Law,et al.  Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. , 2004, Journal of pharmaceutical sciences.

[23]  Bong Kyu Yoo,et al.  Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. , 2007, International journal of pharmaceutics.

[24]  Raj Vuppalanchi,et al.  Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. , 2011, Journal of hepatology.

[25]  R. Bogner,et al.  Formation of physically stable amorphous drugs by milling with Neusilin. , 2003, Journal of pharmaceutical sciences.

[26]  Hoo-Kyun Choi,et al.  Preparation of a solid dispersion of felodipine using a solvent wetting method. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  N. Maleki-Dizaji,et al.  The effect of total extract of Securigera securidaca L. seeds on serum lipid profiles, antioxidant status, and vascular function in hypercholesterolemic rats. , 2009, Journal of ethnopharmacology.

[28]  Maryam Rameshrad,et al.  Physicochemical characterization and pharmacological evaluation of ezetimibe-PVP K30 solid dispersions in hyperlipidemic rats. , 2015, Colloids and surfaces. B, Biointerfaces.

[29]  R. N. Gursoy,et al.  Design and characterization of nanocrystal formulations containing ezetimibe. , 2011, Chemical & pharmaceutical bulletin.

[30]  M. Zhong,et al.  Preparation and evaluation of self‐microemulsifying drug delivery systems (SMEDDS) containing atorvastatin , 2006, The Journal of pharmacy and pharmacology.

[31]  J. M. Marchetti,et al.  Dissolution rate enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersions by solvent methods , 2013 .

[32]  N. Wenger,et al.  Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years , 2014, Lipids in Health and Disease.

[33]  Syed sajjad Hussen,et al.  Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  A. Nokhodchi,et al.  Preparation and Characterization of Solid Dispersions of Piroxicam with Hydrophilic Carriers , 2007, Drug development and industrial pharmacy.

[35]  William M. Lee,et al.  Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations , 2013, Hepatology.

[36]  S. Gattani,et al.  Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS) , 2011, Pharmaceutical development and technology.

[37]  C. Judson King,et al.  Mechanism of stickiness in hygroscopic, amorphous powders , 1982 .

[38]  R. Ross,et al.  Hyperlipidemia and atherosclerosis. , 1976, Science.

[39]  K. Adibkia,et al.  Physicochemical characterization of naproxen solid dispersions prepared via spray drying technology , 2013 .

[40]  R. Roy,et al.  Comparative Study of Ezetimibe and Atorvastatin Alone and in Combination on Lipid Profile in Rats , 2013, Materia socio-medica.

[41]  G. Van den Mooter,et al.  Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. , 2002, International journal of pharmaceutics.

[42]  C. Farley,et al.  Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats , 2003, British journal of pharmacology.

[43]  Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. , 1996 .

[44]  R. Löbenberg,et al.  Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[45]  M. Nagarsenker,et al.  Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  S. Garrigues,et al.  PLS-UV spectrophotometric method for the simultaneous determination of paracetamol, acetylsalicylic acid and caffeine in pharmaceutical formulations , 1997 .

[47]  K. Jeong,et al.  Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. , 2005, The Journal of veterinary medical science.

[48]  Beom-Jin Lee,et al.  Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[49]  P Augustijns,et al.  Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[50]  J. Cook,et al.  Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. , 2008, European journal of pharmacology.

[51]  Kiran Thadkala,et al.  Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability , 2014, International journal of pharmaceutical investigation.

[52]  Ali Nokhodchi,et al.  Cogrinding as an approach to enhance dissolution rate of a poorly water-soluble drug (gliclazide) , 2010 .

[53]  Boyang Yu,et al.  Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. , 2005, Journal of pharmaceutical and biomedical analysis.

[54]  D. Bikiaris,et al.  Optimizing the ability of PVP/PEG mixtures to be used as appropriate carriers for the preparation of drug solid dispersions by melt mixing technique using artificial neural networks: I. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[55]  S. Davaran,et al.  Application of electrospraying as a one-step method for the fabrication of triamcinolone acetonide-PLGA nanofibers and nanobeads. , 2014, Colloids and surfaces. B, Biointerfaces.

[56]  Patrick Augustijns,et al.  Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30 , 1998 .

[57]  Elizabeth M. Brunt,et al.  Pathology of nonalcoholic fatty liver disease , 2010, Nature Reviews Gastroenterology &Hepatology.

[58]  D. Brenner,et al.  Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease , 2011, Gastroenterology research and practice.

[59]  J. Dressman,et al.  New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[60]  Rakesh Patel,et al.  Solid-state characterization and dissolution properties of ezetimibe–cyclodextrins inclusion complexes , 2008 .

[61]  K. Amighi,et al.  Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. , 2005, International journal of pharmaceutics.

[62]  Lynne S. Taylor,et al.  Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions , 1997, Pharmaceutical Research.